Testosterone priming with darolutamide for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether giving a high dose of testosterone before standard hormone therapy can help the treatment work longer for men with prostate cancer that has spread. You would receive testosterone injections for a short time, then a hormone blocker (darolutamide) along with continued testosterone shots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your prostate cancer has come back after initial treatment, with a rising PSA (at least 1.0) and spread seen on a scan.
- You have not had hormone therapy (like Lupron) or oral hormone pills (like Zytiga, Xtandi, or Nubeqa) for cancer that came back or spread.
- You have not had chemotherapy or Pluvicto for your prostate cancer.
- Your liver, kidney, and blood counts are within safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug darolutamide for men whose prostate cancer has spread and is no longer controlled by standard hormone therapy. It may be an option if you've already had certain hormone treatments for at least 12 months but your cancer is still progressing.
This trial tests a combination of high-dose testosterone with enzalutamide and difluoromethylornithine (DFMO) for men whose prostate cancer has spread and stopped responding to standard hormone therapy. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a new combination treatment for men with advanced prostate cancer that has stopped responding to usual hormone therapy. It compares high-dose testosterone followed by darolutamide to standard care, and may help control the cancer longer.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a combination of precise radiation therapy (SBRT) and a drug called darolutamide for men whose prostate cancer has spread to a limited number of other parts of the body. The goal is to see if this approach can control the cancer effectively with fewer side effects.
This trial tests whether adding radiation therapy to the drug darolutamide helps men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy and has spread to a few spots seen on special scans. The study aims to find the best way to control the cancer while keeping side effects manageable.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.